Fortress Biotech, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Fortress Biotech, Inc. stock issued during period, value, new issues for the quarter ending 2024-12-31 was -$74.00K, a 100.83% decline year-over-year.
- Fortress Biotech, Inc. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $7.36M, a 735900.00% increase year-over-year.
- Fortress Biotech, Inc. stock issued during period, value, new issues for the quarter ending 2024-06-30 was -$1.00K.
- Fortress Biotech, Inc. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $10.12M, a 23.31% decline year-over-year.
- Fortress Biotech, Inc. stock issued during period, value, new issues for fiscal 2024 was $17.40M, a 21.20% decline from fiscal 2023.
- Fortress Biotech, Inc. stock issued during period, value, new issues for fiscal 2023 was $22.09M.
- Fortress Biotech, Inc. stock issued during period, value, new issues for fiscal 2016 was $53.00M.
- Fortress Biotech, Inc. stock issued during period, value, new issues for fiscal 2012 was $28.75M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-12-31 | -$74.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $17.40M 10-K · filed 2026-03-31 |
| 2024-09-30 | $7.36M 10-Q · filed 2025-11-14 | $26.41M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $19.05M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $10.12M 10-Q · filed 2025-05-15 | $19.01M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $8.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $22.09M 10-K · filed 2025-03-31 |
| 2023-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | |
| 2023-06-30 | -$41.00K 10-Q · filed 2024-08-13 | |
| 2023-03-31 | $13.19M 10-Q · filed 2024-05-15 | |
| 2016-12-31 | $53.00M 10-K · filed 2018-03-16 | |
| 2016-09-30 | $53.00M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $400.00K 10-Q · filed 2016-08-09 | |
| 2012-12-31 | $28.75M 10-K · filed 2015-03-16 | |
| 2007-12-31 | $2.00K 10-K · filed 2014-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |